Evidence map›Paper›PMID 33019704›Full record

ArticleCancers2020

(2

Jeffrey R Idle, Katja Seipel, Ulrike Bacher, Thomas Pabst, Diren Beyoğlu

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. A Metabolomic Analysis of Cirrhotic Ascites.Molecules (Basel, Switzerland) · 2022
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Jeffrey R IdleArthur G. Zupko's Systems Pharmacology and Pharmacogenomics, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 11201-5423, USA.ORCID 0000-0002-6143-1520
Katja SeipelDepartment of BioMedical Research, University of Bern, 3008 Bern, Switzerland.ORCID 0000-0003-3128-1573
Ulrike BacherDepartment of Hematology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0001-8771-947X
Thomas PabstDepartment of BioMedical Research, University of Bern, 3008 Bern, Switzerland.
Diren BeyoğluArthur G. Zupko's Systems Pharmacology and Pharmacogenomics, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 11201-5423, USA.
University of Bern · CHLong Island University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) frequently harbors mutations in isocitrate 1 (

Indexed as

(2R,3S)-dihydroxybutanoic acid(2R)-hydroxyglutaric acidacute myeloid leukemiabiomarkerisocitrate dehydrogenase 1isocitrate dehydrogenase 2metabolomicsoncometabolite

Identifiers

PMID33019704
PMCPMC7600928
OpenAlexW3089897467

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.